Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

The vitamin K oxidoreductase is a multimer that efficiently reduces vitamin K epoxide to hydroquinone to allow vitamin K-dependent protein carboxylation.

Rishavy MA, Hallgren KW, Wilson LA, Usubalieva A, Runge KW, Berkner KL.

J Biol Chem. 2013 Nov 1;288(44):31556-66. doi: 10.1074/jbc.M113.497297. Epub 2013 Aug 5.

2.

Conserved loop cysteines of vitamin K epoxide reductase complex subunit 1-like 1 (VKORC1L1) are involved in its active site regeneration.

Tie JK, Jin DY, Stafford DW.

J Biol Chem. 2014 Mar 28;289(13):9396-407. doi: 10.1074/jbc.M113.534446. Epub 2014 Feb 13.

3.

The Arg98Trp mutation in human VKORC1 causing VKCFD2 disrupts a di-arginine-based ER retention motif.

Czogalla KJ, Biswas A, Rost S, Watzka M, Oldenburg J.

Blood. 2014 Aug 21;124(8):1354-62. doi: 10.1182/blood-2013-12-545988. Epub 2014 Jun 24.

4.

[Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies].

Loriot MA, Beaune P.

Rev Med Interne. 2006 Dec;27(12):979-82. Epub 2006 Oct 11. Review. French.

PMID:
17070618
5.

Two enzymes catalyze vitamin K 2,3-epoxide reductase activity in mouse: VKORC1 is highly expressed in exocrine tissues while VKORC1L1 is highly expressed in brain.

Caspers M, Czogalla KJ, Liphardt K, Müller J, Westhofen P, Watzka M, Oldenburg J.

Thromb Res. 2015 May;135(5):977-83. doi: 10.1016/j.thromres.2015.01.025. Epub 2015 Jan 26.

7.
8.

VKORC1L1, an enzyme rescuing the vitamin K 2,3-epoxide reductase activity in some extrahepatic tissues during anticoagulation therapy.

Hammed A, Matagrin B, Spohn G, Prouillac C, Benoit E, Lattard V.

J Biol Chem. 2013 Oct 4;288(40):28733-42. doi: 10.1074/jbc.M113.457119. Epub 2013 Aug 8.

9.

A new cell culture-based assay quantifies vitamin K 2,3-epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol-driven VKOR assay.

Fregin A, Czogalla KJ, Gansler J, Rost S, Taverna M, Watzka M, Bevans CG, Müller CR, Oldenburg J.

J Thromb Haemost. 2013 May;11(5):872-80. doi: 10.1111/jth.12185.

10.

Functional study of the vitamin K cycle in mammalian cells.

Tie JK, Jin DY, Straight DL, Stafford DW.

Blood. 2011 Mar 10;117(10):2967-74. doi: 10.1182/blood-2010-08-304303. Epub 2011 Jan 14.

11.

Structural Modeling Insights into Human VKORC1 Phenotypes.

Czogalla KJ, Watzka M, Oldenburg J.

Nutrients. 2015 Aug 14;7(8):6837-51. doi: 10.3390/nu7085313. Review.

12.

VKORC1 and the vitamin K cycle.

Garcia AA, Reitsma PH.

Vitam Horm. 2008;78:23-33. doi: 10.1016/S0083-6729(07)00002-7. Review.

PMID:
18374188
15.

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.

Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Müller CR, Strom TM, Oldenburg J.

Nature. 2004 Feb 5;427(6974):537-41.

PMID:
14765194
16.

VKORC1 deficiency in mice causes early postnatal lethality due to severe bleeding.

Spohn G, Kleinridders A, Wunderlich FT, Watzka M, Zaucke F, Blumbach K, Geisen C, Seifried E, Müller C, Paulsson M, Brüning JC, Oldenburg J.

Thromb Haemost. 2009 Jun;101(6):1044-50.

PMID:
19492146
17.

VKORC1: a warfarin-sensitive enzyme in vitamin K metabolism and biosynthesis of vitamin K-dependent blood coagulation factors.

Wallin R, Wajih N, Hutson SM.

Vitam Horm. 2008;78:227-46. doi: 10.1016/S0083-6729(07)00011-8. Review.

PMID:
18374197
18.

Mycobacterium tuberculosis vitamin K epoxide reductase homologue supports vitamin K-dependent carboxylation in mammalian cells.

Tie JK, Jin DY, Stafford DW.

Antioxid Redox Signal. 2012 Feb 15;16(4):329-38. doi: 10.1089/ars.2011.4043. Epub 2011 Nov 22.

19.

Confirmation of warfarin resistance of naturally occurring VKORC1 variants by coexpression with coagulation factor IX and in silico protein modelling.

Müller E, Keller A, Fregin A, Müller CR, Rost S.

BMC Genet. 2014 Feb 4;15:17. doi: 10.1186/1471-2156-15-17.

20.

Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces.

Czogalla KJ, Biswas A, Wendeln AC, Westhofen P, Müller CR, Watzka M, Oldenburg J.

Blood. 2013 Oct 10;122(15):2743-50. doi: 10.1182/blood-2013-05-501692. Epub 2013 Aug 27.

Supplemental Content

Support Center